echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Positive Tianqing/Kangfang BioPD-1 first-line clinical trial data for advanced liver cell carcinoma were disclosed.

    Positive Tianqing/Kangfang BioPD-1 first-line clinical trial data for advanced liver cell carcinoma were disclosed.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Photo Source: ASCO Summary Collection Research Data to be published at ASCO Is a Ib/II study for Paiamply (200 mg Q3W) in conjunction with hydrochloride anrotini 8 mg, once daily, for 2 consecutive weeks for 1 week (n s 31).
    tumor mitigation assessment uses version 1.1 of the solid tumor efficacy assessment criteria.
    Clinical Research Data (as of January 14, 2020): Clinical efficacy: 31 patients administered in the group at the end of the data deadline, with a median follow-up time of 7.0 months, median to disease progression time of 8.8 months, 6 months without disease The progress rate was 59.8% (95% confidence interval: 35.1%, 77.6%), the median total lifetime has not yet been reached, and the total survival rate for 6 months was 91.6% (95% confidence interval: 69.9%, 97.9%).
    Tumor Response Evaluation: Of the 25 patients who had been evaluated for at least 2 imaging images, the identified objective remission rate (ORR) was 24% and the disease control rate (DCR) was 84%.
    some patients have been treated for up to 11 months and continue to be treated.
    safety: combination therapy is well tolerated and there are no serious adverse events associated with treatment.
    most treatment-related adverse events (TRAE) are at level 1-2 and the incidence of TraE at Level 3 is 12.9%, of which only 1 patient (3.2%) Level 3 hypertension occurred, with only 1 patient (3.2%) Treatment is discontinued due to adverse events associated with treatment.
    so far, insight database shows that Paanpri monotogensis has initiated six clinical trials in the country, including three first-line therapies: combination chemotherapy first-line treatment of non-small cell lung cancer has entered Clinical Phase III, combined chemotherapy first-line treatment of squamous non-small cell lung cancer has entered clinical phase III, and united Anrotinib first-line advanced liver cell cell cancer has entered clinical phase II.
    photo source: Insight Database () Chinese the Director of Oncology Medicine at the Civil Liberation Army General Hospital and lead researcher of the study, Professor Jo Shunchang: The current first-line treatment of non-removable liver cell carcinoma patients is mainly sorafenib and the recently approved Levatini, the total survival of Levalinib is similar to sorafenib, but the total survival rate of sorafenib has been reported at 6 months.
    PD-1 monoanti-ampliad combined with low-dose anti-tumor angiogenesis drug Anrotinib initially showed encouraging efficacy and good safety in patients with non-removable hepatoblastoma.
    disease control rate of DCR is as high as 84%, with a total survival rate of 91.6% over 6 months, and the efficacy is significantly improved.
    combination therapy is safe and controllable, and has potential safety advantages over similar immuno-combined anti-tumor angiogenesis drugs.
    preliminary results of this study suggest that we send ampriated mitatore combined with higher doses of annrotinib, which will have the potential to further improve the clinical efficacy of patients with non-removable hepatocellular carcinoma.
    References: s1. Kudo M. et al Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepato carcinoma: a randomised phase 3 non-systy trial the Lancet 2018; 391: P1163-1173 , Finn, RS.et al Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma New England Journal of Medicine 2020; 382: 1894-1905 382.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.